Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1

EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and reproducing
Excision’s ongoing Phase 1/2 trial is the first clinical evaluation of a CRISPR-based therapy targeting an infectious disease using a multiplexed in vivo gene editing approach
HIV-1 affects 38 million people worldwide, including 1.1 million in the US, with no available cures